Group 1: Investor Relations Activity - The investor relations activity was categorized as a telephone conference [2] - Participants included representatives from Citi PWM and the company's board secretary [2] - The meeting took place on May 15, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main focus was to understand the company's production and operational status [2] - Questions related to the company's performance were addressed during the meeting [2] Group 3: Attendees - Company representatives included the board secretary, a securities affairs representative, and a project manager [2] - The meeting involved direct communication with investors to clarify operational queries [2]

Financial Performance - In 2024, the company achieved a revenue of CNY 40.033 billion, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders reached CNY 4.749 billion, up 16.02% from CNY 4.094 billion in the previous year [2] - The net profit excluding non-recurring items was CNY 4.523 billion, reflecting a 20.18% increase from CNY 3.764 billion [2] - Operating cash flow net amount was CNY 4.297 billion, a growth of 22.68% [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share were CNY 2.66, up 16.16% [3] Dividend Distribution - The company proposed a cash dividend of CNY 11.85 per 10 shares (tax included) based on a total share capital of 1,784,262,603 shares [4] - A special dividend of CNY 12.13 per 10 shares was completed in November 2024, totaling CNY 2.164 billion [4] - The total cash dividend for 2024, including the special dividend, amounts to CNY 23.98 per 10 shares, totaling CNY 4.279 billion, which is 90.09% of the net profit attributable to shareholders [4] Business Strategy - The company focuses on both "internal" and "external" growth strategies, emphasizing strategic mergers and collaborations to enhance its industry portfolio [6] - The aim is to overcome growth bottlenecks and build a sustainable industry portfolio for high-quality development [6] Research and Development - The company is committed to developing both traditional Chinese medicine and innovative drugs, establishing a comprehensive research system for traditional medicinal resources [7] - It aims to create competitive innovative drugs aligned with national and local biopharmaceutical strategies [7] - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with positive results reported in November [8] - The INR102 injection for prostate cancer treatment has also received approval for clinical trials [9]

云南白药集团股份有限公司 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | ☑其他（电话会议） | | 参与单位名称及人员 | KS Fund-Fei Ni,Heartland Capital Management (HK) Limited-Jane Chu，Goldman Sachs Asset Management-Christine Pu & Claire Li， | | 姓名 | New China Asset Management Co., Ltd.-刘婷，Ren Bridge Fund | | | 谢雨阳 | | 时间 | 年 月 日星期四 2025 5 15 | | 地点 | 集团总部办公大楼 | | 上市公司接待人员 | 董事会秘书-钱映辉，证券事务代表-李孟珏，项目管理-张然 | | 投资者关系活动主要 | 了解公司生产经营情况等相关问题 | | 内容介绍 | | | 附件清单 | 会议记录 | 1 / 1 投资者调研会议记录表 编 ...

| | □特定对象调研□分析师会议 | | --- | --- | | | □媒体采访□业绩说明会 | | 投资者关系活动类别 | □新闻发布会□路演活动 | | | □现场参观□一对一沟通 | | | ☑其他（电话会议） | | 参与单位名称及人员 | Allianz Global Investors-Alex Jiang | | 姓名 | | | 时间 | 2025 年 5 月 15 日星期四 | | 地点 | 集团总部办公大楼 | | 上市公司接待人员 | 董事会秘书-钱映辉，证券事务代表-李孟珏，项目管理-张然 | | 投资者关系活动主要 | 了解公司生产经营情况等相关问题 | | 内容介绍 | | | 附件清单 | 会议记录 | 编号：21-2505-01 云南白药集团股份有限公司 投资者调研会议记录表 1 / 1 ...

云南白药集团股份有限公司 投资者调研会议记录 召开方式：电话调研 投资者：Allianz Global Investors-Alex Jiang 时间：2025 年 5 月 15 日 地点：集团总部办公大楼 高原反应的预防与治疗方面的临床研究均取得稳步进展，为产品打开更广 阔应用场景。市场营销方面，培育自有运动 IP'走啊打球去'取得成功， 促进品牌年轻化、单品渗透率进一步提高；气血康包装焕新升级，紧抓秋 冬滋补的重要营销节点，推动气血康口服液销售快速增长。渠道细分方面， 院内渠道持续深耕，获得稳步扩展，线下 OTC 渠道保持优势，线上探索 取得新突破。生产提效方面，建立线上化业务流程，推动实现营销工作精 准化、渠道建设生态化、用户数据自有化，打造制度规范、流程科学、简 洁高效的大后台运营体系，全年提质增效成果显著。 2、健康品事业群渠道建设情况如何？ 答：在健康品方面，公司具有覆盖到终端的、布局完善的全国性大健 康产品销售团队，云南白药牙膏市场份额在国内继续保持领先，在口腔品 类拥有较高品牌渗透力。公司通过不断优化全链路渠道，一方面夯实传统 线下渠道优势，另一方面对即时零售、社区团购、兴趣电商等新兴业态保 ...

Core Viewpoint - The Chinese traditional medicine industry is experiencing collective anxiety due to insufficient effective demand, accelerated industry transformation, policy changes, and intense market competition [1] Industry Performance Overview - The performance of traditional Chinese medicine companies in 2024 and the first quarter of 2025 shows a diverging trend, with some companies achieving stable growth through brand advantages and product innovation, while others face revenue declines and profit pressures [1][3] - In 2024, Baiyunshan led the industry with a revenue of 749.93 billion yuan, but experienced a slight decline of 0.69% year-on-year, indicating growth challenges for traditional giants [3][6] - Yunnan Baiyao and China Resources Sanjiu followed with revenues of 400.33 billion yuan and 276.17 billion yuan, reflecting year-on-year growth rates of 2.36% and 11.63%, respectively [3][6] - In the first quarter of 2025, leading companies continued to show growth, while trailing companies remained under pressure [1][6] Profitability Insights - Yunnan Baiyao reported a net profit of 47.67 billion yuan in 2024, maintaining a growth rate of 15.63%, while Pizhou's net profit reached 29.96 billion yuan, aligning with its revenue growth [6] - Daren Tang emerged as a "profit dark horse" with a net profit increase of 128.68% year-on-year, while Dong'e Ejiao's net profit grew by 25.57% due to product price increases and channel optimization [6][1] R&D and Sales Expenses - In 2024, the highest R&D investment was from Tianshili, amounting to 1.039 billion yuan, representing 12.23% of its revenue [6][7] - Sales expenses were highest for China Resources Sanjiu at 72.20 billion yuan, followed by Baiyunshan at 56.20 billion yuan [7] - The overall R&D investment among the top 20 companies indicates a need for improvement, especially in innovative drug development and modern Chinese medicine technology applications [7] Market Challenges and Strategic Responses - The unique product strategy, once a cash cow for many companies, is now facing challenges due to adjustments in medical insurance directories and expanded centralized procurement [9][10] - Companies like Step Long Pharmaceutical have reported significant losses due to high sales expenses and declining core product revenues [1][6] - The industry is witnessing a trend where companies are either "slimming down" by divesting non-core assets or "bulking up" through mergers and acquisitions to strengthen their market position [14][15] Future Outlook - The ongoing centralized procurement and market dynamics necessitate that companies balance pricing and market share while building brand moats [12][14] - Companies with unique proprietary formulas, such as Pizhou and Yunnan Baiyao, are better positioned to withstand market fluctuations compared to those reliant on single products without strong patent protection [11][12]

| 本次解质 | | | | | | 已质押股份情况 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 本次解质押 | | | | | 占 | | | | | 押及再质 | 公 | 情况 | | 占其所 | | | | | | 持股数量 持股比 | 股东名 | | 及再质押前 | | | 司总 | | 已质押股 | | 占已 | 份 | | 占未 | | | | | | | 押后质押 | | | | 持股 | | | | | | 未质押股份 | 份 | | | | | | | | | 例 | 称 （股） | | 质押股份数 | | | 股本 | 限售和 | | | 质押 | 冻 | | 质押 | | | | | | | 股份数量 | | | | 比 | | | | | | 限售和冻结 | 例 | | | | | | | | | 量（股） | | | | | 比例 | 结、标记数 | | 股 | | 股份 | 份 | | | | | | | | | （股） | | | | | 数量（股） | | | | | | | | | | | 量 ...

股票代码：000538 股票简称：云南白药 公告编号：2025-19 年 5 月 12 日解除质押，详见"一、本次股份解除质押基本情况"。 质押股份是否负担重大资产重组等业绩补偿义务：否。 云南白药集团股份有限公司 关于股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）于 近日接到公司股东新华都实业集团股份有限公司（以下简称"新华都"） 的通知，获悉新华都将其持有的公司部分股份办理了解除质押及再质押。 具体情况如下： | 股东名称 | 是否为控股股 东或第一大股 | 本次解除质押 /冻结/拍卖等 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人/申请 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其一致行 动人 | 股份数量 | 比例 | 比例 | | | 人等 | | 新华都实业 集团股份有 | 否 | 290,514,000 | 66.67% | 16.28% | 20 ...

为进一步加强与投资者的互动交流，云南白药集团股份有限公司（以下简 称"公司"）将参加由云南证监局指导，云南省上市公司协会与深圳市全景网 络有限公司联合举办的"2024 年度云南辖区上市公司投资者网上集体接待日"， 现将相关事项公告如下： 股票代码：000538 股票简称：云南白药 公告编号：2025-18 云南白药集团股份有限公司 关于参加云南辖区上市公司 2024 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 5 月 16 日（周五）16:00-17:00。届时 公司部分高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况 和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与！ 特此公告 云南白药集团股份有限公司 董 事 会 2025 年 5 月 12 日 1 / 1 ...

风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 价投观察员 来源：雪球 2025年一季度财报一出 ， 中药界的两大 " 顶流 " —— 片仔癀和云南白药 ， 又双叒叕被拉出 来 " 比美 " 了 。 一个靠 " 一粒药卖760元 " 撑起千亿市值 ， 一个靠 " 牙膏卖到全国第一 " 稳坐日化头把交椅 。 这俩活宝的财报 ， 就像两个性格迥异的学霸 ： 一个闷声发大财 ， 一个 卷到飞起 。 咱们今天就来扒一扒 ， 到底谁更 " 能打 " ！ 一 、 赚钱能力 ： 片仔癀 " 抠门 " 但会过日子 ， 云南白药 " 大方 " 但利润狂飙 片仔癀 ： 一季度营收31.42亿元 ， 同比下滑0.92% ， 但净利润10亿元 ， 反而涨了2.59% 。 这操作就像 " 奶茶店销量降了 ， 但涨价+省广告费 ， 利润反而更高 " —— 毛利率从47%降到 45% ， 但销售费用直接砍了38% ， 最终每卖100元能净赚32元 ， 比去年还多赚0.8元 。 把 我惊的直呼 ： " 这波操作 ， 666 ！ " 云南白药 ： 营收108.41亿元 ， 同比微增0.62% ， ...